KBI-BIOPHARMA
6.7.2022 13:47:10 CEST | Business Wire | Press release
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO signs Definitive Agreement to Acquire Enerflex APAC Operations, Expanding Service Capabilities in the Asia-Pacific Region26.2.2026 07:34:00 CET | Press release
INNIO Group, a leading energy solution and service provider, today announced it has signed a definitive agreement with Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) to acquire their aftermarket business operations in Australia, Thailand and Indonesia. The transaction advances INNIO’s strategy to strengthen its presence in the Asia-Pacific (APAC) region and enhance customer proximity. The transaction is subject to customary closing conditions and regulatory approvals. Closing is expected during the second half of 2026. The Enerflex APAC aftermarket business operates principally in three countries and eight locations. The company offers extensive workshop and office space, as well as a strong installed base. This base is supported by long-term service agreements with major oil and gas companies. Dr. Dennis Schulze, CFO of INNIO Group, commented: “By integrating Enerflex’s expertise in the APAC region, we strengthen our service portfolio, deliver greater customer value, and accelerate growth in A
Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle26.2.2026 07:16:00 CET | Press release
12M 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225107874/en/ Oliver Bäte, Chief Executive Officer of Allianz SEExcellent momentum and record operating profitTotal business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever Shareholders’ core net income advances 10.9 percent to 11.1 billion euros Core earnings per share (EPS) grow 12.5 percent and reach 28.61 euros Core return on equity (RoE) reaches an excellent level of 18.1 percent Solvency IIratio2 increases 10 percentage points to 218 percent supported by excellent capital generation 4Q 2025 Diversified growth and double-digit increase in shareholders’ core net incomeTotal business volume rises 6.5 1 percent with contributions from all segments Operating profit increases 3.0 percent to 4.3 billion euros, driven by excelle
Tigo Energy Showcases Real-time Active Commissioning Software at KEY 2026 Expo26.2.2026 06:00:00 CET | Press release
Next-generation commissioning system designed to help streamline solar installations delivers another Total Quality Solar innovation as Tigo expands installer loyalty program Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo,” “Company”), a leading provider of intelligent solar and energy software solutions, today announced the Company’s presence as an exhibitor at the 2026 KEY – The Energy Transition Expo in Rimini, Italy, where Tigo will preview the new active commissioning software. From basic solar-only installations to advanced solar-plus-storage configurations, the system supports installers throughout the entire jobsite workflow via the Tigo EI App, delivering on-site guidance, real-time progress visibility, and clear verification of every required step to help reduce delays, truck rolls, and commissioning uncertainty. At KEY 2026, Tigo will also showcase the latest expansions to the Installer Loyalty Program, including new eligibility tiers and segments, enhanced data support for install
Indra Group Exceeds All Its Guidances in 2025 and Sets Even More Ambitious Guidances for 2026 Than Those Set Out in Its 'Leading the Future' Strategic Plan25.2.2026 23:08:00 CET | Press release
Results in fiscal year 2025Revenues increased by 13%, totaling €5.457 billion in 2025Indra Group sets financial guidances at least 17% higher than those foreseen in its Strategic Plan for 2026Indra Group announces thepayment of a €0.30 dividend per share (more than 20% above the dividend in 2024) charged to the earnings posted in 2025The results and the increase in the order intake confirm Indra Group’s industrial strength and its capacity to tackle and execute the major defence modernization programs Indra Group (MAD:IDR): • The fourth-quarter order intake in 2025 totaled €8.329 billion, raising thefull-year backlog to €16.083 billion (122% more than in 2024). The Defence backlog stood at €11.336 billion, far exceeding the target of more than €10 billion set for 2026. • Revenues increased by 13% in 2025 with respect to 2024, with double-digit year-on-year rises in Defence, ATM and Mobility Revenues recorded a 28% year-on-year rise in the final quarter of the year • EBITDA and EBIT rec
Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series25.2.2026 19:00:00 CET | Press release
Including five ‘Designed for Samsung’ accessories plus more, the collection is engineered and optimized specifically for the Samsung Galaxy S26 seriesFrom fast Qi2 25W charging to Nano-Titan–enhanced screen protection, each product is engineered for everyday performance and durabilityThe lineup reinforces Belkin’s role as a trusted partner for next-generation Galaxy devices Belkin, a leading consumer electronics brand for over 40 years, today announced a new collection of accessories designed and optimized specifically for the Samsung Galaxy S26 series. From fast, reliable Qi2 25W charging to advanced screen protection engineered for ultrasonic fingerprint sensors and next-generation displays, every product in the collection is designed to meet the demands of Galaxy S26 users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225459906/en/ Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series ‘Designed f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom